Search

Your search keyword '"Willekens, Christophe"' showing total 199 results
Start Over Author "Willekens, Christophe" Search Limiters Available in Library Collection
199 results on '"Willekens, Christophe"'

2. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Author

Danlos, François-Xavier, Grajeda-Iglesias, Claudia, Durand, Sylvère, Sauvat, Allan, Roumier, Mathilde, Cantin, Delphine, Colomba, Emeline, Rohmer, Julien, Pommeret, Fanny, Baciarello, Giulia, Willekens, Christophe, Vasse, Marc, Griscelli, Frank, Fahrner, Jean-Eudes, Goubet, Anne-Gaëlle, Dubuisson, Agathe, Derosa, Lisa, Nirmalathasan, Nitharsshini, Bredel, Delphine, Mouraud, Séverine, Pradon, Caroline, Stoclin, Annabelle, Rozenberg, Flore, Duchemin, Jérôme, Jourdi, Georges, Ellouze, Syrine, Levavasseur, Françoise, Albigès, Laurence, Soria, Jean-Charles, Barlesi, Fabrice, Solary, Eric, André, Fabrice, Pène, Frédéric, Ackerman, Félix, Mouthon, Luc, Zitvogel, Laurence, Marabelle, Aurélien, Michot, Jean-Marie, Fontenay, Michaela, and Kroemer, Guido

Published
2024
Full Text
View/download PDF

3. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

Author

Hermine, Olivier, Mariette, Xavier, Ravaud, Philippe, Bureau, Serge, Dougados, Maxime, Resche-Rigon, Matthieu, Tharaux, Pierre-Louis, Tibi, Annick, Azoulay, Elie, Cadranel, Jacques, Emmerich, Joseph, Fartoukh, Muriel, Guidet, Bertrand, Humbert, Marc, Lacombe, Karine, Mahevas, Matthieu, Pene, Frédéric, Porcher, Raphaël, Pourchet-Martinez, Valerie, Schlemmer, Frédéric, Yazdanpanah, Yazdan, Baron, Gabriel, Perrodeau, Elodie, Vanhoye, Damien, Kedzia, Cécile, Demerville, Lauren, Gysembergh-Houal, Anne, Bourgoin, Alexandre, Raked, Nabil, Mameri, Lakhdar, Montlahuc, Claire, Biard, Lucie, Alary, St.phanie, Hamiria, Samir, Bariz, Thinhinane, Semri, Hala, Hai, Dhiaa Meriem, Benafla, Moustafa, Belloul, Mohamed, Vauboin, Pernelle, Flamand, Saskia, Pacheco, Claire, Walter-Petrich, Anouk, Stan, Emilia, Benarab, Souad, Nyanou, Corine, Charreteur, Robin, Dupre, Céline, Cardet, Kévin, Lehmann, Blandine, Baghli, Kamyl, Madelaine, Claire, D'Ortenzio, Eric, Puéchal, Oriane, Semaille, Caroline, Savale, Laurent, Harrois, Anatole, Figueiredo, Samy, Duranteau, Jacques, Anguel, Nadia, Pavot, Arthur, Monnet, Xavier, Richard, Christian, Teboul, Jean-Louis, Durand, Philippe, Tissieres, Pierre, Jevnikar, Mitja, Montani, David, Pavy, Stephan, Nocturne, Gaétane, Bitoun, Samuel, Noel, Nicolas, Lambotte, Olivier, Escaut, Lelia, Jauréguiberry, Stephane, Baudry, Elodie, Verny, Christiane, Lefevre, Edouard, Zaidan, Mohamad, Molinari, Domitille, Leprun, Gaël, Fourreau, Alain, Cylly, Laurent, Grimaldi, Lamiae, Virlouvet, Myriam, Meftali, Ramdane, Fabre, Soléne, Licois, Marion, Mamoune, Asmaa, Boudali, Yacine, Le Tiec, Clotilde, Verstuyft, Céline, Roques, Anne-Marie, Georgin-Lavialle, Sophie, Senet, Patricia, Pialoux, Gilles, Soria, Angele, Parrot, Antoine, François, Helene, Rozensztajn, Nathalie, Blin, Emmanuelle, Choinier, Pascaline, Camuset, Juliette, Rech, Jean-Simon, Canellas, Antony, Rolland-Debord, Camille, Lemarié, Nadege, Belaube, Nicolas, Nadal, Marine, Siguier, Martin, Petit-Hoang, Camille, Chas, Julie, Drouet, Elodie, Lemoine, Matthieu, Phibel, Audrey, Aunay, Lucie, Bertrand, Eliane, Ravato, Sylviane, Vayssettes, Marie, Adda, Anne, Wilpotte, Celine, Thibaut, Pélagie, Fillon, Julie, Debrix, Isabelle, Fellahi, Soraya, Bastard, Jean-Philippe, Lefévre, Guillaume, Gottenberg, Jacques-Eric, Hansmann, Yves, Blanc, Frédéric, Ohlmann-Caillard, Sophie, Castelain, Vincent, Chatelus, Emmanuel, Chatron, Eva, Collange, Olivier, Danion, François, De Blay, Frédéric, Diemunsch, Pierre, Diemunsch, Sophie, Felten, Renaud, Goichot, Bernard, Greigert, Valentin, Guffroy, Aurelien, Heger, Bob, Kaeuffer, Charlotte, Kassegne, Loic, Korganow, Anne Sophie, Le Borgne, Pierrick, Lefebvre, Nicolas, Mertes, Paul-Michel, Noll, Eric, Oberlin, Mathieu, Poindron, Vincent, Pottecher, Julien, Ruch, Yvon, Weill, François, Meyer, Nicolas, Andres, Emmanuel, Demonsant, Eric, Tayebi, Hakim, Nisand, Gabriel, Brin, Stéphane, Sublon, Cédric, Becker, Guillaume, Hutt, Anne, Martin, Tristan, Bayer, Sophie, Metzger, Catherine, Mekinian, Arsene, Abisror, Noémie, Adedjouma, Amir, Bollens, Diane, Bonneton, Marion, Bourcicaux, Nathalie, Bourrier, Anne, Thibault Chiarabiani, Maria Chauchard, Chopin, Doroth.e, Cohen, Jonathan, Devred, Ines, Donadille, Bruno, Fain, Olivier, Hariri, Geoffrey, Jachiet, Vincent, Ingliz, Patrick, Garnier, Marc, Gatfosse, Marc, Ghrenassia, Etienne, Gobert, Delphine, Krause le Garrec, Jessica, Landman, Cecilia, Lavillegrand, Jean Remy, Lefebvre, Benedicte, Mahevas, Thibault, Mazerand, Sandie, Meynard, Jean Luc, Morgand, Marjolaine, Ouaz.ne, Zineb, Pacanowski, Jerome, Riviere, S.bastien, Seksik, Philippe, Sokol, Harry, Soliman, Heithem, Valin, Nadia, Urbina, Thomas, McAvoy, Chloé, Miranda, Maria Pereira, Aratus, Gladys, Berard, Laurence, Simon, Tabassome, Nguyen, Anne Daguenel, Girault, Elise, Mayala-Kanda, Cl.mentine, Antignac, Marie, Leplay, Céline, Arlet, Jean-Benoit, Diehl, Jean-Luc, Bellenfant, Florence, Blanchard, Anne, Buffet, Alexandre, Cholley, Bernard, Fayol, Antoine, Flamarion, Edouard, Godier, Anne, Gorget, Thomas, Hamada, Sophie-Rym, Hauw-Berlemont, Caroline, Hulot, Jean-Sébastien, Lebeaux, David, Livrozet, Marine, Michon, Adrien, Neuschwander, Arthur, Pennet, Marie-Aude, Planquette, Benjamin, Ranque, Brigitte, Sanchez, Olivier, Volle, Geoffroy, Briois, Sandrine, Cornic, Mathias, Elisee, Virginie, Denis, Jesuthasan, Djadi-Prat, Juliette, Jouany, Pauline, Junquera, Ramon, Henriques, Mickael, Kebir, Amina, Lehir, Isabelle, Meunier, Jeanne, Patin, Florence, Paquet, Val.rie, Tréhan, Anne, Vigna, Véronique, Sabatier, Brigitte, Bergerot, Damien, Jouve, Charléne, Knosp, Camille, Lenoir, Olivia, Mahtal, Nassim, Resmini, Léa, Lescure, Xavier, Ghosn, Jade, Bachelard, Antoine, Rachline, Anne, Isernia, Valentina, Bao-chau, Phung, Vallois, Dorothée, Sautereau, Aurelie, Neukrich, Catherine, Dossier, Antoine, Borie, Raphaël, Crestani, Bruno, Ducrocq, Gregory, Steg, Philippe Gabriel, Dieude, Philippe, Papo, Thomas, Marcault, Estelle, Chaudhry, Marhaba, Da Silveira, Charléne, Metois, Annabelle, Mahenni, Ismahan, Meziani, Meriam, Nilusmas, Cyndie, Le Gac, Sylvie, Ndiaye, Awa, Louni, Fran.oise, Chansombat, Malikhone, Julia, Zelie, Chalal, Solaya, Chalal, Lynda, Kramer, Laura, Le Grand, Jeniffer, Ouifiya, Kafif, Piquard, Valentine, Tubiana, Sarah, Nguyen, Yann, Honsel, Vasco, Weiss, Emmanuel, Codorniu, Anais, Zarrouk, Virginie, de Lastours, Victoire, Uzzan, Matthieu, Gamany, Naura, Claveirole, Agathe, Navid, Alexandre, Fouque, Tiffanie, Cohen, Yonathan, Lupo, Maya, Gilles, Constance, Rahli, Roza, Louis, Zeina, Boutboul, David, Galicier, Lionel, Amara, Yaël, Archer, Gabrielle, Benattia, Amira, Bergeron, Anne, Bondeelle, Louise, de Castro, Nathalie, Clément, Melissa, Darmon, Michaël, Denis, Blandine, Dupin, Clairelyne, Feredj, Elsa, Feyeux, Delphine, Joseph, Adrien, Lenglin, Etienne, Le Guen, Pierre, Liégeon, Geoffroy, Lorillon, Gwenaël, Mabrouki, Asma, Mariotte, Eric, Martin de Frémont, Grégoire, Mirouse, Adrien, Molina, Jean-Michel, Peffault de Latour, Régis, Oksenhendler, Eric, Saussereau, Julien, Tazi, Abdellatif, Tudesq, Jean-Jacques, Zafrani, Lara, Brindele, Isabelle, Bugnet, Emmanuelle, Lebras, Karine Celli, Chabert, Julien, Djaghout, Lamia, Fauvaux, Catherine, Jegu, Anne Lise, Kozakiewicz, Ewa, Meunier, Martine, Tremorin, Marie-Thérèse, Davoine, Claire, Madelaine, Isabelle, Caillat-Zucman, Sophie, Delaugerre, Constance, Morin, Florence, Sène, Damien, Burlacu, Ruxandra, Chousterman, Benjamin, Mégarbanne, Bruno, Richette, Pascal, Riveline, Jean-Pierre, Frazier, Aline, Vicaut, Eric, Berton, Laure, Hadjam, Tassadit, Vazquez-Ibarra, Miguel Alejandro, Jourdaine, Clément, Tran, Olivia, Jouis, Véronique, Jacob, Aude, Smati, Julie, Renaud, Stéphane, Pernin, Claire, Suarez, Lydia, Semerano, Luca, Abad, Sébastien, nainous, Ruben B., Bonnet, Nicolas, Comparon, Celine, Cohen, Yves, Cordel, Hugues, Dhote, Robin, Dournon, Nathalie, Duchemann, Boris, Ebstein, Nathan, Gille, Thomas, Giroux-Leprieur, Benedicte, Goupil de Bouille, Jeanne, Nunes, Hilario, Oziel, Johanna, Roulot, Dominique, Sese, Lucile, ClaireTantet, Uzunhan, Yurdagul, Bloch-Queyrat, Coralie, Levy, Vincent, Messani, Fadhila, Rahaoui, Mohammed, Petit, Myléne, Brahmi, Sabrina, Rathoin, Vanessa, Rigal, Marthe, Costedoat-Chalumeau, Nathalie, Luong, Liem Binh, Hamou, Zakaria Ait, Benghanem, Sarah, Blanche, Philippe, Carlier, Nicolas, Chaigne, Benjamin, Gauzit, Remy, Joumaa, Hassan, Jozwiak, Mathieu, Lachétre, Marie, Lafoeste, Hélène, Launay, Odie, Legendre, Paul, Marey, Jonathan, Morbieu, Caroline, Palmieri, Lola-Jade, Szwebel, Tali-Anne, Abdoul, Hendy, Bruneau, Alexandra, Beclin-Clabaux, Audrey, Larrieu, Charly, Montanari, Pierre, Dufour, Eric, Clarke, Ada, Le Bourlout, Catherine, Marin, Nathalie, Menage, Nathalie, Saleh-Mghir, Samira, Cisse, Mamadou Salif, Cheref, Kahina, Guerin, Corinne, Zerbit, Jérémie, Michel, Marc, Gallien, Sébastien, Crickx, Etienne, Le Vavasseur, Benjamin, Kempf, Emmanuelle, Jaffal, Karim, Vindrios, William, Oniszczuk, Julie, Guillaud, Constance, Lim, Pascal, Fois, Elena, Melica, Giovanna, Matignon, Marie, Jalabert, Maud, Lelièvre, Jean-Daniel, Schmitz, David, Bourhis, Marion, Belazouz, Sylia, Languille, Laetitia, Boucle, Caroline, Cita, Nelly, Didier, Agnés, Froura, Fahem, Ledudal, Katia, Sadaoui, Thiziri, Thiemele, Alaki, Le Febvre De Bailly, Delphine, Verlinde, Muriel Carvhalo, Mayaux, Julien, Cacoub, Patrice, Saadoun, David, Vautier, Mathieu, Bugaut, Héléne, Benveniste, Olivier, Allenbach, Yves, Leroux, Gaëlle, Rigolet, Aude, Guillaume-Jugnot, Perrine, Domont, Fanny, Desbois, Anne Claire, Comarmond, Chloé, Champtiaux, Nicolas, Toquet, Segolene, Ghembaza, Amine, Vieira, Matheus, Maalouf, Georgina, Boleto, Goncalo, Ferfar, Yasmina, Corvol, Jean-Christophe, Louapre, C.line, Sambin, Sara, Mariani, Louise-Laure, Karachi, Carine, Tubach, Florence, Estellat, Candice, Gimeno, Linda, Martin, Karine, Bah, Aicha, Keo, Vixra, Ouamri, Sabrine, Messaoudi, Yasmine, Yelles, Nessima, Faye, Pierre, Cavelot, Sebastien, Larcheveque, Cecile, Annonay, Laurence, Benhida, Jaouad, Zahrate-Ghoul, Aida, Hammal, Soumeya, Belilita, Ridha, Charbonnier, Fanny, Aguilar, Claire, Alby-Laurent, Fanny, Burger, Carole, Campos-Vega, Clara, Chavarot, Nathalie, Fournier, Benjamin, Rouzaud, Claire, Vimpére, Damien, Elie, Caroline, Bakouboula, Prissile, Choupeaux, Laure, Granville, Sophie, Issorat, Elodie, Broissand, Christine, Alyanakian, Marie-Alexandra, Geri, Guillaume, Derridj, Nawal, Sguiouar, Naima, Meddah, Hakim, Djadel, Mourad, Chambrin-Lauvray, Héléne, Duclos-vallée, Jean-Charles, Saliba, Faouzi, Sacleux, Sophie-Caroline, Kounis, Ilias, Tamazirt, Sonia, Rudant, Eric, Michot, Jean-Marie, Stoclin, Annabelle, Colomba, Emeline, Pommeret, Fanny, Willekens, Christophe, Da Silva, Rosa, Dejean, Valérie, Mekid, Yasmina, Ben-Mabrouk, Ines, Netzer, Florence, Pradon, Caroline, Drouard, Laurence, Camara-Clayette, Valérie, Morel, Alexandre, Garcia, Gilles, Mohebbi, Abolfazl, Berbour, Férial, Dehais, Mélanie, Pouliquen, Anne-Lise, Klasen, Alison, Soyez-Herkert, Loren, London, Jonathan, Keroumi, Younes, Guillot, Emmanuelle, Grailles, Guillaume, El amine, Younes, Defrancq, Fanny, Fodil, Hanane, Bouras, Chaouki, Dautel, Dominique, Gambier, Nicolas, Dieye, Thierno, Bienvenu, Boris, Lancon, Victor, Lecomte, Laurence, Beziriganyan, Kristina, Asselate, Belkacem, Allanic, Laure, Kiouris, Elena, Legros, Marie-Héléne, Lemagner, Christine, Martel, Pascal, Provitolo, Vincent, Ackermann, Félix, Le Marchand, Mathilde, Chan Hew Wai, Aurélie, Fremont, Dimitri, Coupez, Elisabeth, Adda, Mireille, Duée, Frédéric, Bernard, Lise, Gros, Antoine, Henry, Estelle, Courtin, Claire, Pattyn, Anne, Guinot, Pierre-Grégoire, Bardou, Marc, Maurer, Agnes, Jambon, Julie, Cransac, Amélie, Pernot, Corinne, Mourvillier, Bruno, Marquis, Eric, Benoit, Philippe, Roux, Damien, Gernez, Coralie, Yelnik, Cécile, Poissy, Julien, Nizard, Mandy, Denies, Fanette, Gros, Helene, Mourad, Jean-Jacques, Sacco, Emmanuelle, Renet, Sophie, Ader, F., Yazdanpanah, Y., Mentre, F., Peiffer-Smadja, N., Lescure, F.X., Poissy, J., Bouadma, L., Timsit, J.F., Lina, B., Morfin-Sherpa, F., Bouscambert, M., Gaymard, A., Peytavin, G., Abel, L., Guedj, J., Andrejak, C., Burdet, C., Laouenan, C., Belhadi, D., Dupont, A., Alfaiate, T., Basli, B., Chair, A., Laribi, S., Level, J., Schneider, M., Tellier, M.C., Dechanet, A., Costagliola, D., Terrier, B., Ohana, M., Couffin-Cadiergues, S., Esperou, H., Delmas, C., Saillard, J., Fougerou, C., Moinot, L., Wittkop, L., Cagnot, C., Le Mestre, S., Lebrasseur-Longuet, D., Petrov-Sanchez, V., Diallo, A., Mercier, N., Icard, V., Leveau, B., Tubiana, S., Hamze, B., Gelley, A., Noret, M., D’Ortenzio, E., Puechal, O., Semaille, C., Welte, T., Paiva, J.A., Halanova, M., Kieny, M.P., Balssa, E., Birkle, C., Gibowski, S., Landry, E., Le Goff, A., Moachon, L., Moins, C., Wadouachi, L., Paul, C., Levier, A., Bougon, D., Djossou, F., Epelboin, L., Dellamonica, J., Marquette, C.H., Robert, C., Gibot, S., Senneville, E., Jean-Michel, V., Zerbib, Y., Chirouze, C., Boyer, A., Cazanave, C., Gruson, D., Malvy, D., Andreu, P., Quenot, J.P., Terzi, N., Faure, K., Chabartier, C., Le Moing, V., Klouche, K., Ferry, T., F, Valour, Gaborit, B., Canet, E., Le Turnier, P., Boutoille, D., Bani-Sadr, F., Benezit, F., Revest, M., Cameli, C., Caro, A., Um Tegue, MJ Ngo, Le Tulzo, Y., Laviolle, B., Laine, F., Thiery, G., Meziani, F., Hansmann, Y., Oulehri, W., Tacquard, C., Vardon-Bounes, F., Riu-Poulenc, B., Murris-Espin, M., Bernard, L., Garot, D., Hinschberger, O., Martinot, M., Bruel, C., Pilmis, B., Bouchaud, O., Loubet, P., Roger, C., Monnet, X., Figueiredo, S., Godard, V., Mira, J.P., Lachatre, M., Kerneis, S., Aboab, J., Sayre, N., Crockett, F., Lebeaux, D., Buffet, A., Diehl, J.L., Fayol, A., Hulot, J.S., Livrozet, M., Dessap, A Mekontso, Ficko, C., Stefan, F., Le Pavec, J., Mayaux, J., Ait-Oufella, H., Molina, J.M., Pialoux, G., Fartoukh, M., Textoris, J., Brossard, M., Essat, A., Netzer, E., Riault, Y., Ghislain, M., Beniguel, L., Genin, M., Gouichiche, L., Betard, C., Belkhir, L., Altdorfer, A., Centro, V Fraipont, Braz, S., Ribeiro, JM Ferreira, Alburqueque, R Roncon, Berna, M., Alexandre, M., Lamprecht, B., Egle, A., Greil, R., Joannidis, M., Patterson, Thomas F., Ponce, Philip O., Taylor, Barbara S., Patterson, Jan E., Bowling, Jason E., Javeri, Heta, Kalil, Andre C., Larson, LuAnn, Hewlett, Angela, Mehta, Aneesh K., Rouphael, Nadine G., Saklawi, Youssef, Scanlon, Nicholas, Traenkner, Jessica J., Trible, Ronald P., Jr., Walter, Emmanuel B., Ivey, Noel, Holland, Thomas L., Ruiz-Palacios, Guillermo M., Ponce de León, Alfredo, Rajme, Sandra, Hsieh, Lanny, Amin, Alpesh N., Watanabe, Miki, Lee, Helen S., Kline, Susan, Billings, Joanne, Noren, Brooke, Kim, Hyun, Bold, Tyler D., Tapson, Victor, Grein, Jonathan, Sutterwala, Fayyaz, Iovine, Nicole, Beattie, Lars K., Wakeman, Rebecca Murray, Shaw, Matthew, Jain, Mamta K., Mocherla, Satish, Meisner, Jessica, Luque, Amneris, Sweeney, Daniel A., Benson, Constance A., Ali, Farhana, Atmar, Robert L., El Sahly, Hana M., Whitaker, Jennifer, Falsey, Ann R., Branche, Angela R., Rozario, Cheryl, Pineda, Justino Regalado, Martinez-Orozco, José Arturo, Lye, David Chien, Ong, Sean WX., Chia, Po Ying, Young, Barnaby E., Sandkovsky, Uriel, Berhe, Mezgebe, Haley, Clinton, Dishner, Emma, Cantos, Valeria D., Kelley, Colleen F., Rebolledo Esteinou, Paulina A., Kandiah, Sheetal, Doernberg, Sarah B., Crouch, Pierre-Cedric B., Jang, Hannah, Luetkemeyer, Anne F., Dwyer, Jay, Cohen, Stuart H., Thompson, George R., 3rd, Nguyen, Hien H., Finberg, Robert W., Wang, Jennifer P., Perez-Velazquez, Juan, Wessolossky, Mireya, Jackson, Patrick E.H., Bell, Taison D., West, Miranda J., Taiwo, Babafemi, Krueger, Karen, Perez, Johnny, Pearson, Triniece, Paules, Catharine I., Julian, Kathleen G., Ahmad, Danish, Hajduczok, Alexander G., Arguinchona, Henry, Arguinchona, Christa, Erdmann, Nathaniel, Goepfert, Paul, Ahuja, Neera, Frank, Maria G., Wyles, David, Young, Heather, Oh, Myoung-don, Park, Wan Beom, Kang, Chang Kyung, Marconi, Vincent, Moanna, Abeer, Cribbs, Sushma, Harrison, Telisha, Kim, Eu Suk, Jung, Jongtak, Song, Kyoung-Ho, Kim, Hong Bin, Tan, Seow Yen, Shafi, Humaira, Chien, Jaime, Fong, Raymond KC., Murray, Daniel D., Lundgren, Jens, Nielsen, Henrik, Jensen, Tomas, Zingman, Barry S., Grossberg, Robert, Riska, Paul F., Yang, Otto O., Ahn, Jenny, Arias, Rubi, Rapaka, Rekha R., Hauser, Naomi, Campbell, James D., Short, William R., Tebas, Pablo, Baron, Jillian T., McLellan, Susan L.F., Blanton, Lucas S., Seashore, Justin B., Creech, C. Buddy, Rice, Todd W., Walker, Shannon, Thomsen, Isaac P., Lopez de Castilla, Diego, Van Winkle, Jason W., Riedo, Francis X., Pada, Surinder Kaur, Wang, Alvin DY., Lin, Li, Harkins, Michelle, Mertz, Gregory, Sosa, Nestor, Ann Chai, Louis Yi, Tambyah, Paul Anantharajah, Tham, Sai Meng, Archuleta, Sophia, Yan, Gabriel, Lindholm, David A., Markelz, Ana Elizabeth, Mende, Katrin, Mularski, Richard, Hohmann, Elizabeth, Torres-Soto, Mariam, Jilg, Nikolaus, Maves, Ryan C., Utz, Gregory C., George, Sarah L., Hoft, Daniel F., Brien, James D., Paredes, Roger, Mateu, Lourdes, Loste, Cora, Kumar, Princy, Thornton, Sarah, Mohanraj, Sharmila, Hynes, Noreen A., Sauer, Lauren M., Colombo, Christopher J., Schofield, Christina, Colombo, Rhonda E., Chambers, Susan E., Novak, Richard M., Wendrow, Andrea, Gupta, Samir K., Lee, Tida, Lalani, Tahaniyat, Holodniy, Mark, Chary, Aarthi, Huprikar, Nikhil, Ganesan, Anuradha, Ohmagari, Norio, Mikami, Ayako, Price, D. Ashley, Duncan, Christopher J.A., Dierberg, Kerry, Neumann, Henry J., Taylor, Stephanie N., Lacour, Alisha, Masri, Najy, Swiatlo, Edwin, Widmer, Kyle, Neaton, James D., Bessesen, Mary, Stephens, David S., Burgess, Timothy H., Uyeki, Timothy M., Walker, Robert, Marks, G. Lynn, Osinusi, Anu, Cao, Huyen, Cardoso, Anabela, de Bono, Stephanie, Schlichting, Douglas E., Chung, Kevin K., Ferreira, Jennifer L., Green, Michelle, Makowski, Mat, Wierzbicki, Michael R., Conrad, Tom M., El-Khorazaty, Jill Ann, Hill, Heather, Bonnett, Tyler, Gettinger, Nikki, Engel, Theresa, Lewis, Teri, Wang, Jing, Beigel, John H., Tomashek, Kay M., Ghazaryan, Varduhi, Beresnev, Tatiana, Nayak, Seema, Dodd, Lori E., Dempsey, Walla, Nomicos, Effie, Lee, Marina, Pikaart-Tautges, Rhonda, Elsafy, Mohamed, Jurao, Robert, Koo, Hyung, Proschan, Michael, Yokum, Tammy, Arega, Janice, Florese, Ruth, Voell, Jocelyn D., Davey, Richard, Serrano, Ruth C., Wiley, Zanthia, Phadke, Varun K., Goepfert, Paul A., Gomez, Carlos A., Sofarelli, Theresa A., Certain, Laura, Imlay, Hannah N., Wolfe, Cameron R., Ko, Emily R., Engemann, John J., Felix, Nora Bautista, Wan, Claire R., Elmor, Sammy T., Bristow, Laurel R., Harkins, Michelle S., Iovine, Nicole M., Elie-Turenne, Marie-Carmelle, Tapson, Victor F., Choe, Pyoeng Gyun, Mularski, Richard A., Rhie, Kevin S., Hussein, Rezhan H., Ince, Dilek, Winokur, Patricia L., Takasaki, Jin, Saito, Sho, McConnell, Kimberly, Wyles, David L., Sarcone, Ellen, Grimes, Kevin A., Perez, Katherine, Janak, Charles, Whitaker, Jennifer A., Rebolledo, Paulina A., Gharbin, John, Lambert, Allison A., Zea, Diego F., Bainbridge, Emma, Hostler, David C., Hostler, Jordanna M., Shahan, Brian T., Ling, Evelyn, Go, Minjoung, Hubbard, Fleesie A., Chakrabarty, Melony, Laguio-Vila, Maryrose, Walsh, Edward E., Guirgis, Faheem, Marconi, Vincent C., Madar, Christian, Borgetti, Scott A., Levine, Corri, Nock, Joy, Candiotti, Keith, Rozman, Julia, Dangond, Fernando, Hyvert, Yann, Seitzinger, Andrea, Cross, Kaitlyn, Pettibone, Stephanie, Nayak, Seema U., Deye, Gregory A., Siempos, Ilias I., Belhadi, Drifa, Veiga, Viviane Cordeiro, Cavalcanti, Alexandre Biasi, Branch-Elliman, Westyn, Papoutsi, Eleni, Gkirgkiris, Konstantinos, Xixi, Nikoleta A., and Kotanidou, Anastasia

Published
2024
Full Text
View/download PDF

4. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Author

Danlos, François-Xavier, Grajeda-Iglesias, Claudia, Durand, Sylvère, Sauvat, Allan, Roumier, Mathilde, Cantin, Delphine, Colomba, Emeline, Rohmer, Julien, Pommeret, Fanny, Baciarello, Giulia, Willekens, Christophe, Vasse, Marc, Griscelli, Frank, Fahrner, Jean-Eudes, Goubet, Anne-Gaëlle, Dubuisson, Agathe, Derosa, Lisa, Nirmalathasan, Nitharsshini, Bredel, Delphine, Mouraud, Séverine, Pradon, Caroline, Stoclin, Annabelle, Rozenberg, Flore, Duchemin, Jérôme, Jourdi, Georges, Ellouze, Syrine, Levavasseur, Françoise, Albigès, Laurence, Soria, Jean-Charles, Barlesi, Fabrice, Solary, Eric, André, Fabrice, Pène, Frédéric, Ackerman, Félix, Mouthon, Luc, Zitvogel, Laurence, Marabelle, Aurélien, Michot, Jean-Marie, Fontenay, Michaela, and Kroemer, Guido

Published
2021
Full Text
View/download PDF

5. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

Author

Lucas, Nolwenn, Duchmann, Matthieu, Rameau, Philippe, Noël, Floriane, Michea, Paula, Saada, Véronique, Kosmider, Olivier, Pierron, Gérard, Fernandez-Zapico, Martin E, Howard, Matthew T., King, Rebecca L., Niyongere, Sandrine, Diop, M’boyba Khadija, Fenaux, Pierre, Itzykson, Raphael, Willekens, Christophe, Ribrag, Vincent, Fontenay, Michaela, Padron, Eric, Soumelis, Vassili, Droin, Nathalie, Patnaik, Mrinal M, and Solary, Eric

Published
2019
Full Text
View/download PDF

6. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes

Author

Willekens, Christophe, primary, Chahine, Claude, additional, Dragani, Matteo, additional, Khalife‐Hachem, Sabine, additional, Bigenwald, Camille, additional, Rossignol, Julien, additional, Castilla‐Llorente, Cristina, additional, Danu, Alina, additional, Michot, Jean‐Marie, additional, Saada, Veronique, additional, Cotteret, Sophie, additional, Marzac, Christophe, additional, Renneville, Aline, additional, Plo, Isabelle, additional, Broutin, Sophie, additional, Bosselut, Nelly, additional, Cassinat, Bruno, additional, Lazarovici, Julien, additional, Droin, Nathalie, additional, and De Botton, Stephane, additional

Published
2023
Full Text
View/download PDF

7. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Author

Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, and Tallman, Martin S.

Published
2017
Full Text
View/download PDF

8. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

Author

Willekens, Christophe, Renneville, Aline, Broutin, Sophie, Saada, Véronique, Micol, Jean-Baptiste, Delahousse, Julia, Poinsignon, Vianney, Bories, Claire, Berthon, Céline, Itzykson, Raphael, Boissel, Nicolas, Quivoron, Cyril, Terroir-Cassou-Mounat, Marie, Bosq, Jacques, Preudhomme, Claude, Paci, Angelo, Penard-Lacronique, Virginie, and De Botton, Stéphane

Published
2018
Full Text
View/download PDF

9. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Author

Quek, Lynn, David, Muriel D., Kennedy, Alison, Metzner, Marlen, Amatangelo, Michael, Shih, Alan, Stoilova, Bilyana, Quivoron, Cyril, Heiblig, Maël, Willekens, Christophe, Saada, Véronique, Alsafadi, Samar, Vijayabaskar, M. S., Peniket, Andy, Bernard, Oliver A., Agresta, Sam, Yen, Katharine, MacBeth, Kyle, Stein, Eytan, Vassiliou, George S., Levine, Ross, De Botton, Stephane, Thakurta, Anjan, Penard-Lacronique, Virginie, and Vyas, Paresh

Published
2018
Full Text
View/download PDF

10. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies

Author

Bigenwald, Camille, primary, Haddad, Yacine, additional, Thelemaque, Cassandra, additional, Carrier, Agathe, additional, Birebent, Roxanne, additional, Ly, Pierre, additional, Flament, Caroline, additional, Lahmar, Imran, additional, de Sousa, Eric, additional, Maeurer, Markus, additional, Miyara, Makoto, additional, Assi, Tarek, additional, Castilla-Llorente, Cristina, additional, Willekens, Christophe, additional, Fayemi, Céline, additional, Lazarovici, Julien, additional, Marabelle, Aurélien, additional, Derosa, Lisa, additional, Ribrag, Vincent, additional, and Zitvogel, Laurence, additional

Published
2023
Full Text
View/download PDF

11. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Author

Selimoglu-Buet, Dorothée, Wagner-Ballon, Orianne, Saada, Véronique, Bardet, Valérie, Itzykson, Raphaël, Bencheikh, Laura, Morabito, Margot, Met, Elisabeth, Debord, Camille, Benayoun, Emmanuel, Nloga, Anne-Marie, Fenaux, Pierre, Braun, Thorsten, Willekens, Christophe, Quesnel, Bruno, Adès, Lionel, Fontenay, Michaela, Rameau, Philippe, Droin, Nathalie, Koscielny, Serge, and Solary, Eric

Published
2015
Full Text
View/download PDF

12. Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Author

Willekens, Christophe, primary, Chraibi, Samy, additional, Decroocq, Justine, additional, Carpentier, Benjamin, additional, Lebon, Delphine, additional, Bonnet, Sarah, additional, Gauthier, Nicolas, additional, Pagès, Arnaud, additional, Dragani, Matteo, additional, Khalife-Hachem, Sabine, additional, Micol, Jean-Baptiste, additional, Pasquier, Florence, additional, Wickenhauser, Stefan, additional, Saada, Véronique, additional, Vergé, Véronique, additional, Arbab, Ahmadreza, additional, Marzac, Christophe, additional, Pascal, Laurent, additional, Roos-Weil, Damien, additional, Jourdan, Eric, additional, Bouscary, Didier, additional, and de Botton, Stéphane, additional

Published
2022
Full Text
View/download PDF

14. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes

Author

Willekens, Christophe, primary, Laplane, Lucie, additional, Dagher, Tracy, additional, Benlabiod, Camélia, additional, Lacout, Catherine, additional, Rameau, Philippe, additional, Catelain, Cyril, additional, Alfaro, Alexia, additional, Edmond, Valérie, additional, Signolle, Nicolas, additional, Silvin, Aymeric, additional, Ginhoux, Florent, additional, Marchand, Valentine, additional, Droin, Nathalie, additional, Hoogenboezem, Remco, additional, Schneider, Rebekka K., additional, Penson, Alexander V, additional, Abdel-Wahab, Omar, additional, Gonin, Patrick, additional, Marty, Caroline, additional, Plo, Isabelle, additional, Villeval, Jean-Luc, additional, Porteu, Francoise, additional, Vainchenker, William, additional, and Solary, Eric, additional

Published
2021
Full Text
View/download PDF

15. Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Author

Khalife-Hachem, Sabine, primary, Saleh, Khalil, additional, Pasquier, Florence, additional, Willekens, Christophe, additional, Tarabay, Anthony, additional, Antoun, Leony, additional, Grinda, Thomas, additional, Castilla-Llorente, Cristina, additional, Duchmann, Matthieu, additional, Quivoron, Cyril, additional, Auger, Nathalie, additional, Saada, Veronique, additional, Delaloge, Suzette, additional, Leary, Alexandra, additional, Renneville, Aline, additional, Antony-Debre, Ileana, additional, Rosselli, Filippo, additional, De Botton, Stéphane, additional, Salviat, Flore, additional, Marzac, Christophe, additional, and Micol, Jean-Baptiste, additional

Published
2021
Full Text
View/download PDF

17. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

Author

Kayser, Sabine, primary, Schlenk, Richard F., additional, Lebon, Delphine, additional, Carre, Martin, additional, Götze, Katharina S., additional, Stölzel, Friedrich, additional, Berceanu, Ana, additional, Schäfer-Eckart, Kerstin, additional, Peterlin, Pierre, additional, Hicheri, Yosr, additional, Rahme, Ramy, additional, Raffoux, Emmanuel, additional, Chermat, Fatiha, additional, Krause, Stefan W., additional, Aulitzky, Walter E., additional, Rigaudeau, Sophie, additional, Noppeney, Richard, additional, Berthon, Celine, additional, Görner, Martin, additional, Jost, Edgar, additional, Carassou, Philippe, additional, Keller, Ulrich, additional, Orvain, Corentin, additional, Braun, Thorsten, additional, Saillard, Colombe, additional, Arar, Ali, additional, Kunzmann, Volker, additional, Wemeau, Mathieu, additional, De Wit, Maike, additional, Niemann, Dirk, additional, Bonmati, Caroline, additional, Schwänen, Carsten, additional, Abraham, Julie, additional, Aljijakli, Ahmad, additional, Haiat, Stephanie, additional, Krämer, Alwin, additional, Reichle, Albrecht, additional, Gnadler, Martina, additional, Willekens, Christophe, additional, Spiekermann, Karsten, additional, Hiddemann, Wolfgang, additional, Müller-Tidow, Carsten, additional, Thiede, Christian, additional, Röllig, Christoph, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Baldus, Claudia D., additional, Lengfelder, Eva, additional, Fenaux, Pierre, additional, Platzbecker, Uwe, additional, and Adès, Lionel, additional

Published
2021
Full Text
View/download PDF

18. Coopération entre les mutations Jak2 V617F et Srsf2 P95Hdans le système hématopoïétique

Author

Willekens, Christophe and STAR, ABES

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, SRSF2, JAK2, [SDV.CAN] Life Sciences [q-bio]/Cancer, Signalisation, Modèles murins, Épissage, Signalling, Neoplasmes myéloprolifératifs, Splicing, Myeloproliferative neoplasms, Mouse model
Abstract

JAK2 V617F mutation is frequently identified in myeloproliferative neoplasms (MPN). Additional somatic variants are supposed to contribute to bone marrow fibrosis or acute myeloid leukemia evolution. One of these mutations affects SRSF2, a gene encoding a component of the splicing machinery. To investigate how Jak2 V617F and Srsf2 P95H mutations interact in the hematopoietic tissue, we generated conditional knock-in mice in which the two mutations were expressed upon the control of Scl gene. Our study shows that Srsf2 P95H mutation initially exhibits limited effect on Jak2 V617F polycythemia and thrombocytosis but induces a delay in myelofibrosis development and protect hematopoietic stem cell from exhaustion observed after serial transplantation in Jak2 V617F single mutant cells. We focused on megakaryocyte (MK), implied in fibrosis development and found that Srsf2P95H partially reversed MKabnormalities induced by Jak2 V617F (cell size, normalized ploidy and expression of c-Mpl). Analysis of c-Mpl/Jak2 signaling with mass cytometry revealed a slight reduced proportion of MK expressing high levels of P-Stat5 in case of Srsf2 P95H co-occurrence with Jak2 V617F while treatment with high dose of the thrombopoietin-mimetic romiplostim in mice transplanted with wild-type or Srsf2 P95H bone marrow cells confirms the negative impact of Srsf2 P95H on fibrosis development. Gene expression analysis on sorted MK confirms down-regulation of Jak/Stat signaling pathway induced by Srsf2 P95H and reveals that Srsf2 P95H mutation more frequently induces exon 14 skipping of Jak2 mRNA. These result was confirmed in granulocytes samples from patients with JAK2 V617F MPN with associated SRSF2 P95H mutation., La mutation JAK2 V617F est fréquemment observée en cas de néoplasme myéloprolifératif (NMP). D’autres mutations somatiques peuvent être associées et sont corrélées au stade myélofibrotique ou à une évolution en leucémie aigüe. L’une de ces mutations touche le gène SRSF2, codant pour une protéine du complexe d’épissage. Pour étudier l’interaction entre les mutations Jak2 V617F et Srsf2 P95H dans le tissu hématopoïétique, nous avons généré un modèle murin knock-in conditionnel des deux mutations s’exprimant sous le contrôle du gène Scl. Notre étude montre que Srsf2 P95H limite peu le développement de la polyglobulie et de la thrombocytose induites par Jak2 V617F mais freine l’évolution vers une fibrose médullaire et protège les cellules souches hématopoïétiques de l’épuisement en transplantations sériées. L’étude des mégacaryocytes (MK), impliqués dans le processus fibrotique, montre que Srsf2 P95H induit une quasi-normalisation des anomalies induites par Jak2 V617F (taille, ploïdisation, expression de c-Mpl). L’analyse de la signalisation c-Mpl/Jak2 par cytométrie de masse révèle une discrète diminution de la proportion de MK exprimant de haut niveau de P-Stat5 en cas de mutation Srsf2 P95H associée à Jak2 V617F tandis que l’injection d’un agoniste de la thrombopoïetine à fortes doses confirme l’impact négatif de Srsf2 P95H sur le développement de la fibrose. L’étude de l’expression génique de MK triés confirme l’altération de la voie Jak/Stat induite par Srsf2 P95H et révèle que Srsf2 P95H induit plus fréquemment une perte de l’exon 14 (incluant la mutation V617F) de l’ARNm de Jak2. Ce résultat est confirmé sur des échantillons de granulocytes de patients atteints de NMP JAK2 V617F avec mutation SRSF2 P95H associée.

Published
2021

19. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Author

Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio Segura, Cecilia del Carmen, Molinero, César, Mascaró, Cristina, Vila, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch José, Francesc Xavier, The University of Manchester, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Salamero O, Carpio C, Bosch F] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Montesinos P] Hospital Universitari I Politécnic La Fe, València, Spain. Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain. [Willekens C] Institut Gustave Roussy, Villejuif Cedex, France. [Pérez-Simón JA] Hospital Universitario Virgen del Rocío, Sevilla, Spain. Instituto de Biomedicina de Sevilla (Insitituto de Biomedicina De Sevilla/Consejo Superior De Investigaciones Científicas/Centro de Investigación Biomédica en Red de Cáncer), Universidad de Sevilla, Sevilla, Spain. [Pigneux A] Centre Hospitalier Universitaire CHU Bordeaux, Hôpital du Haut Lévêque, Pessac, France. [Récher C] Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France, Vall d'Hebron Barcelona Hospital Campus, Ministerio de Economía y Competitividad (España), European Commission, Cancer Research UK, Centro para el Desarrollo Tecnológico Industrial (España), National Institute for Health Research (UK), University College London, and NIHR Biomedical Research Centre (UK)

Subjects
Adult, Male, Cancer Research, Myeloid, Lysine-Specific Histone Demethylase 1A, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos [COMPUESTOS QUÍMICOS Y DROGAS], neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES], Refractory, In vivo, Recurrence, hemic and lymphatic diseases, medicine, Hematologic Malignancy, Humans, Other subheadings::/therapeutic use [Other subheadings], Enzyme Inhibitors, Aged, Aged, 80 and over, Histone Demethylases, business.industry, Leucèmia mieloide aguda, Otros calificadores::/uso terapéutico [Otros calificadores], Myeloid leukemia, Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute [DISEASES], KDM1A, ORIGINAL REPORTS, Middle Aged, medicine.disease, In vitro, Leukemia, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Oncology, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors [CHEMICALS AND DRUGS], Cancer research, Female, business, Inhibidors enzimàtics - Ús terapèutic
Abstract

[Purpose] Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML)., [Methods] This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor., [Results] Twenty-seven patients were treated with iadademstat on days 1 to 5 (5-220 µg/m2/d) of each week in 28-day cycles in a DE phase that resulted in a recommended dose of 140 µg/m2/d of iadademstat as a single agent. This dose was chosen to treat all patients (n = 14) in an EC enriched with patients with MLL/KMT2A-rearranged AML. Most adverse events (AEs) were as expected in R/R AML and included myelosuppression and nonhematologic AEs, such as infections, asthenia, mucositis, and diarrhea. PK data demonstrated a dose-dependent increase in plasma exposure, and PD data confirmed a potent time- and exposure-dependent induction of differentiation biomarkers. Reductions in blood and bone marrow blast percentages were observed, together with induction of blast cell differentiation, in particular, in patients with MLL translocations. One complete remission with incomplete count recovery was observed in the DE arm., [Conclusion] Iadademstat exhibits a good safety profile together with signs of clinical and biologic activity as a single agent in patients with R/R AML. A phase II trial of iadademstat in combination with azacitidine is ongoing (EudraCT No.: 2018-000482-36)., Supported by Oryzon Genomics and IPT-2012-0673-010000 of the INNPACTO program of the Spanish Ministry of Economy and Competitiveness, with contribution of Fondo Europeo de Desarrollo Regional (FEDER) from the European Union and CDTI_CIIP-20131005/EUROSTAR_E18159. T.C.P.S. is supported by Cancer Research UK Grant No. C5759/A20971. R.P. is supported by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre.

Published
2020

20. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study

Author

Kayser, Sabine, Schlenk, Richard F., Lebon, Delphine, Carre, Martin, Götze, Katharina S., Stölzel, Friedrich, Berceanu, Ana, Schäfer-Eckart, Kerstin, Peterlin, Pierre, Hicheri, Yosr, Rahme, Ramy, Raffoux, Emmanuel, Chermat, Fatiha, Krause, Stefan W., Aulitzky, Walter E., Rigaudeau, Sophie, Noppeney, Richard, Berthon, Celine, Görner, Martin, Jost, Edgar, Carassou, Philippe, Keller, Ulrich, Orvain, Corentin, Braun, Thorsten, Saillard, Colombe, Arar, Ali, Kunzmann, Volker, Wemeau, Mathieu, De Wit, Maike, Niemann, Dirk, Bonmati, Caroline, Schwänen, Carsten, Abraham, Julie, Aljijakli, Ahmad, Haiat, Stephanie, Krämer, Alwin, Reichle, Albrecht, Gnadler, Martina, Willekens, Christophe, Spiekermann, Karsten, Hiddemann, Wolfgang, Müller-Tidow, Carsten, Thiede, Christian, Röllig, Christoph, Serve, Hubert, Bornhäuser, Martin, Baldus, Claudia D., Lengfelder, Eva, Fenaux, Pierre, Platzbecker, Uwe, and Adès, Lionel

Subjects
ddc
Published
2020

21. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening

Author

Hueso, Thomas, Ekpe, Kenneth, Mayeur, Camille, Gatse, Anna, Joncquel-Chevallier Curt, Marie, Gricourt, Guillaume, Rodriguez, Christophe, Burdet, Charles, Ulmann, Guillaume, Neut, Christel, Amini, Salah-Eddine, Lepage, Patricia, Raynard, Bruno, Willekens, Christophe, Micol, Jean-Baptiste, de Botton, Stéphane, Yakoub-Agha, Ibrahim, Gottrand, Frédéric, Desseyn, Jean-Luc, Thomas, Muriel, Woerther, Paul-Louis, Seguy, David, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Universitaire de Lille (CHU Lille), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Emergence de la résistance bactérienne in vivo (EA3964), Université Paris Diderot - Paris 7 (UPD7), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Institut Gustave Roussy (IGR), Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Centre hospitalier universitaire Henri-Mondor [Créteil], Dynamic Microbiology - EA 7380 (DYNAMIC), École nationale vétérinaire - Alfort (ENVA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est (UPE)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University Hospital of Lille, MSD, École nationale vétérinaire d'Alfort (ENVA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Lille, and Tâche, Roselyne

Subjects
Adult, Male, [SDV]Life Sciences [q-bio], Mice, Transgenic, chemotherapy, Feces, Mice, mucus, Antineoplastic Combined Chemotherapy Protocols, microbiota, Animals, Humans, acute leukemia, Intestinal Mucosa, lcsh:RC799-869, Aged, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Induction Chemotherapy, Middle Aged, Fatty Acids, Volatile, Gastrointestinal Microbiome, [SDV] Life Sciences [q-bio], Leukemia, Myeloid, Acute, intestinal barrier, Dysbiosis, Female, lcsh:Diseases of the digestive system. Gastroenterology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Research Article, Research Paper
Abstract

International audience; Induction chemotherapy (7 + 3 regimen) remains the gold standard for patients with acute myeloid leukemia (AML) but is responsible for gut damage leading to several complications such as bloodstream infection (BSI). We aimed to investigate the impact of induction chemotherapy on the intestinal barrier of patients with AML and in wild-type mice. Next, we assessed the potential benefit of strengthening the mucosal barrier in transgenic mice releasing a recombinant protein able to reinforce the mucus layer (Tg222). In patients, we observed a decrease of plasma citrulline, which is a marker of the functional enterocyte mass, of short-chain fatty acids and of fecal bacterial load, except forEscherichia coliandEnterococcusspp., which became dominant. Both the alpha and beta-diversities of fecal microbiota decreased. In wild-type mice, citrulline levels decreased under chemotherapy along with an increase ofE. coliandEnterococcusspp load associated with concomitant histologic impairment. By comparison with wild-type mice, Tg222 mice, 3 days after completing chemotherapy, had higher citrulline levels, a faster healing epithelium, and preserved alpha-diversity of their intestinal microbiota. This was associated with reduced bacterial translocations. Our results highlight the intestinal damage and the dysbiosis induced by the 7 + 3 regimen. As a proof of concept, our transgenic model suggests that strengthening the intestinal barrier is a promising approach to limit BSI and improve AML patients' outcome.

Published
2020

23. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Author

Universidad de Sevilla. Departamento de Medicina, Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, Somervaille, Tim C.P., Universidad de Sevilla. Departamento de Medicina, Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, and Somervaille, Tim C.P.

Abstract

PURPOSE Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML). METHODS This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor. RESULTS Twenty-seven patients were treated with iadademstat on days 1 to 5 (5-220 µg/m2/d) of each week in 28-day cycles in a DE phase that resulted in a recommended dose of 140 µg/m2/d of iadademstat as a single agent. This dose was chosen to treat all patients (n = 14) in an EC enriched with patients with MLL/KMT2A-rearranged AML. Most adverse events (AEs) were as expected in R/R AML and included myelosuppression and nonhematologic AEs, such as infections, asthenia, mucositis, and diarrhea. PK data demonstrated a dose-dependent increase in plasma exposure, and PD data confirmed a potent time- and exposure-dependent induction of differentiation biomarkers. Reductions in blood and bone marrow blast percentages were observed, together with induction of blast cell differentiation, in particular, in patients with MLL translocations. One complete remission with incomplete count recovery was observed in the DE arm. CONCLUSION Iadademstat exhibits a good safety profile together with signs of clinical and biologic activity as a single agent in patients with R/R AML. A phase II trial of iadademstat in combination with azacitidine is ongoing .

Published
2020

24. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Author

Ministerio de Economía y Competitividad (España), European Commission, Cancer Research UK, Centro para el Desarrollo Tecnológico Industrial (España), National Institute for Health Research (UK), University College London, NIHR Biomedical Research Centre (UK), Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José A., Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio, Cecilia, Molinero, César, Mascaró, Cristina, Vila Grajales, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch, Francesc, Somervaille, Tim C. P., Ministerio de Economía y Competitividad (España), European Commission, Cancer Research UK, Centro para el Desarrollo Tecnológico Industrial (España), National Institute for Health Research (UK), University College London, NIHR Biomedical Research Centre (UK), Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José A., Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio, Cecilia, Molinero, César, Mascaró, Cristina, Vila Grajales, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch, Francesc, and Somervaille, Tim C. P.

Abstract

[Purpose] Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML)., [Methods] This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor., [Results] Twenty-seven patients were treated with iadademstat on days 1 to 5 (5-220 µg/m2/d) of each week in 28-day cycles in a DE phase that resulted in a recommended dose of 140 µg/m2/d of iadademstat as a single agent. This dose was chosen to treat all patients (n = 14) in an EC enriched with patients with MLL/KMT2A-rearranged AML. Most adverse events (AEs) were as expected in R/R AML and included myelosuppression and nonhematologic AEs, such as infections, asthenia, mucositis, and diarrhea. PK data demonstrated a dose-dependent increase in plasma exposure, and PD data confirmed a potent time- and exposure-dependent induction of differentiation biomarkers. Reductions in blood and bone marrow blast percentages were observed, together with induction of blast cell differentiation, in particular, in patients with MLL translocations. One complete remission with incomplete count recovery was observed in the DE arm., [Conclusion] Iadademstat exhibits a good safety profile together with signs of clinical and biologic activity as a single agent in patients with R/R AML. A phase II trial of iadademstat in combination with azacitidine is ongoing (EudraCT No.: 2018-000482-36).

Published
2020

27. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Author

Silvin, Aymeric, primary, Chapuis, Nicolas, additional, Dunsmore, Garett, additional, Goubet, Anne-Gaëlle, additional, Dubuisson, Agathe, additional, Derosa, Lisa, additional, Almire, Carole, additional, Hénon, Clémence, additional, Kosmider, Olivier, additional, Droin, Nathalie, additional, Rameau, Philippe, additional, Catelain, Cyril, additional, Alfaro, Alexia, additional, Dussiau, Charles, additional, Friedrich, Chloé, additional, Sourdeau, Elise, additional, Marin, Nathalie, additional, Szwebel, Tali-Anne, additional, Cantin, Delphine, additional, Mouthon, Luc, additional, Borderie, Didier, additional, Deloger, Marc, additional, Bredel, Delphine, additional, Mouraud, Severine, additional, Drubay, Damien, additional, Andrieu, Muriel, additional, Lhonneur, Anne-Sophie, additional, Saada, Véronique, additional, Stoclin, Annabelle, additional, Willekens, Christophe, additional, Pommeret, Fanny, additional, Griscelli, Frank, additional, Ng, Lai Guan, additional, Zhang, Zheng, additional, Bost, Pierre, additional, Amit, Ido, additional, Barlesi, Fabrice, additional, Marabelle, Aurélien, additional, Pène, Frédéric, additional, Gachot, Bertrand, additional, André, Fabrice, additional, Zitvogel, Laurence, additional, Ginhoux, Florent, additional, Fontenay, Michaela, additional, and Solary, Eric, additional

Published
2020
Full Text
View/download PDF

28. Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments

Author

Barlesi, Fabrice, primary, Foulon, Stéphanie, additional, Bayle, Arnauld, additional, Gachot, Bertrand, additional, Pommeret, Fanny, additional, Willekens, Christophe, additional, Stoclin, Annabelle, additional, Merad, Mansouria, additional, GriscelliI, Franck, additional, Micol, Jean-Baptise, additional, Sun, Roger, additional, Nihouarn, Thomas, additional, Balleygier, Corinne, additional, André, Fabrice, additional, Scotte, Florian, additional, Besse, Benjamin, additional, Soria, Jean-Charles, additional, and Albiges, Laurence, additional

Published
2020
Full Text
View/download PDF

29. 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma

Author

Federici, Laetitia, primary, Capelle, Laurent, additional, Annereau, Maxime, additional, Bielle, Franck, additional, Willekens, Christophe, additional, Dehais, Caroline, additional, Laigle-Donadey, Florence, additional, Hoang-Xuan, Khê, additional, Delattre, Jean-Yves, additional, Idbaih, Ahmed, additional, Lemare, Francois, additional, de Botton, Stéphane, additional, Sanson, Marc, additional, and Touat, Mehdi, additional

Published
2020
Full Text
View/download PDF

30. Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Author

Khalife-Hachem, Sabine, primary, Saleh, Khalil, additional, Pasquier, Florence, additional, Tarabay, Anthony, additional, Quivoron, Cyril, additional, Cotteret, Sophie, additional, Willekens, Christophe, additional, Saada, Veronique, additional, Vaz-Luis, Ines-Maria, additional, Delaloge, Suzette, additional, Leary, Alexandra, additional, Raslova, Hana, additional, Rosselli, Filippo, additional, Caron, Olivier, additional, Antony-Debre, Iléana, additional, Solary, Eric, additional, de Botton, Stephane, additional, Marzac, Christophe, additional, and Micol, Jean-Baptiste, additional

Published
2019
Full Text
View/download PDF

31. A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset

Author

Selimoglu-Buet, Dorothée, Rivière, Julie, Ghamlouch, Hussein, Bencheikh, Laura, Lacout, Catherine, Morabito, Margot, Diop, M’boyba, Meurice, Guillaume, Breckler, Marie, Chauveau, Aurélie, Debord, Camille, Debeurme, Franck, Itzykson, Raphael, Chapuis, Nicolas, Willekens, Christophe, Wagner-Ballon, Orianne, Bernard, Olivier A., Droin, Nathalie, Solary, Eric, Hématopoïèse normale et pathologique (U1170 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Plateforme de Bioinformatique [Gustave Roussy], Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etude du Polymorphisme des Génomes Végétaux (EPGV), Institut National de la Recherche Agronomique (INRA), Service d'Hématologie Biologique [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Hématopoïèse normale et pathologique, Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Direction des systèmes d'information, Ministére des Affaires Etrangères, Ministère de l'Europe et des Affaires étrangères (MEAE), Service d'Hématologie Clinique [CHU Lille], Hôpital Claude Huriez, CHU Henri Mondor, Université Paris-Sud 11 - Faculté de médecine (UP11 UFR Médecine), Centre de Recherches Juridiques de l'Université de Franche-Comté - UFC (EA 3225) (CRJFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC), Département d'hématologie [Gustave Roussy], and Institut Gustave Roussy (IGR)

Subjects
Male, Mice, Knockout, Gene Expression Regulation, Leukemic, Science, Primary Cell Culture, Down-Regulation, Leukemia, Myelomonocytic, Chronic, [SDV.CAN]Life Sciences [q-bio]/Cancer, DNA Methylation, Article, Monocytes, Dioxygenases, DNA-Binding Proteins, Mice, MicroRNAs, Proto-Oncogene Proteins, Animals, Humans, Female, lcsh:Q, K562 Cells, Promoter Regions, Genetic, lcsh:Science
Abstract

Non-classical monocyte subsets may derive from classical monocyte differentiation and the proportion of each subset is tightly controlled. Deregulation of this repartition is observed in diverse human diseases, including chronic myelomonocytic leukemia (CMML) in which non-classical monocyte numbers are significantly decreased relative to healthy controls. Here, we identify a down-regulation of hsa-miR-150 through methylation of a lineage-specific promoter in CMML monocytes. Mir150 knock-out mice demonstrate a cell-autonomous defect in non-classical monocytes. Our pulldown experiments point to Ten-Eleven-Translocation-3 (TET3) mRNA as a hsa-miR-150 target in classical human monocytes. We show that Tet3 knockout mice generate an increased number of non-classical monocytes. Our results identify the miR-150/TET3 axis as being involved in the generation of non-classical monocytes., A decrease in the fraction of non-classical monocytes is a hallmark of chronic myelomonocytic leukaemia. Taking advantage of this abnormal situation, the authors identify a mechanistic link between miR-150 and TET3 as being involved in monocyte subset generation.

Published
2018

32. Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report.

Author

Corfmat, Marion, Willekens, Christophe, Vinit, Julien, Bussone, Guillaume, Fenaux, Pierre, Fain, Olivier, Klatzmann, David, Mekinian, Arsene, Comont, Thibault, and malignancies), MINHEMON (French network of dysimmune disorders associated to hematological

Subjects
*STEROID drugs, *MYELODYSPLASTIC syndromes, *DISEASE progression, *INTERLEUKIN-2, *SYSTEMIC inflammatory response syndrome, *TREATMENT effectiveness, *IMMUNOLOGIC diseases, *T cells, *DRUG side effects, *DISEASE complications, *SYMPTOMS, *EVALUATION
Abstract

Objectives Systemic inflammatory and autoimmune diseases can be associated with myelodysplastic syndromes. Current treatments (steroids, immunosuppressive agents, biologics) are unsatisfactory because of their low response rate, dependence or adverse events. We aimed at evaluating the effects of low doses of IL-2 (ld-IL2) as a regulatory T-cell inducer in this context. Methods We treated three patients with ld-IL2 with myelodysplastic syndromes and an associated dysimmune disorder (polymyalgia rheumatic, relapsing polychondritis associated with Sweet's syndrome and vasculitis with cutaneous and joint involvement, respectively). All three patients were dependent on steroids and refractory to biologics or azacitidine. They received doses of 1–1.5 million units of proleukin/day during 5 days and then every fortnight. Results The treatment led to a clinical improvement and steroid sparing in 2/3 patients with no serious adverse events, and no progression of the disease. Conclusion Our results support the investigation of ld-IL2 in MDS associated with immune disorders in controlled clinical studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case report

Author

Wacrenier Agnès, Guerry Mary-Jane, Cornelius Aurélie, Willekens Christophe, and Fourrier François

Subjects
Medicine
Abstract

Abstract Introduction Hemophagocytic lymphohistiocytosis induced by viral diseases is a well recognized entity. Severe forms of H5N1 influenza are known to be associated with symptoms very similar to a reactive hemophagocytic syndrome. We report a case of fulminant lymphohistiocytosis associated with the pandemic A (H1N1) variant. Case presentation A 42-year-old Caucasian woman developed a syndrome of fatal hemophagocytic lymphohistiocytosis shortly after H1N1 influenza. Initial symptoms of the viral disease were unusual, with acute abdominal involvement. Our patient's course was complicated by diffuse skin rash and ileal ischemia. Our patient died of refractory shock and multi-organ failure. Skin, ileum and colon histology was consistent with an acute apoptosis combined with an increased cellular regeneration. Conclusions Influenza may be complicated by severe forms of hemophagocytic lymphohistiocytosis. To ensure early recognition and treatment, physicians should be aware of the possible induction of the syndrome by the novel H1N1 variant. The rapid occurrence of a multi-organ involvement with evocative biological features of macrophage activation should alert clinicians.

Published
2011
Full Text
View/download PDF

34. ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Author

Pegliasco, Jean, primary, Panneau-Schmaltz, Barbara, additional, Martin, Jean-Edouard, additional, Chraibi, Samy, additional, Legoupil, Clemence, additional, Pasquier, Florence, additional, Willekens, Christophe, additional, Bera, Odile, additional, Caron, Olivier, additional, Bourhis, Jean-Henri, additional, Tang, Roseline, additional, Ben-Ali, Adel, additional, Lopez, Maureen, additional, Cotteret, Sophie, additional, Saada, Veronique, additional, Auger, Nathalie, additional, Delaunay, Jacques, additional, Cornillet-Lefebvre, Pascale, additional, Recher, Christian, additional, de Botton, Stephane, additional, Vainchenker, William, additional, Fuseau, Pascal, additional, Benabelali, Raouf, additional, Helias, Philippe, additional, Marzac, Christophe, additional, Plo, Isabelle, additional, Meniane, Jean-Come, additional, Bellanné-Chantelot, Christine, additional, and Micol, Jean-Baptiste, additional

Published
2018
Full Text
View/download PDF

35. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening.

Author

Hueso, Thomas, Ekpe, Kenneth, Mayeur, Camille, Gatse, Anna, Joncquel-Chevallier Curt, Marie, Gricourt, Guillaume, Rodriguez, Christophe, Burdet, Charles, Ulmann, Guillaume, Neut, Christel, Amini, Salah-Eddine, Lepage, Patricia, Raynard, Bruno, Willekens, Christophe, Micol, Jean-Baptiste, De Botton, Stéphane, Yakoub-Agha, Ibrahim, Gottrand, Frédéric, Desseyn, Jean-Luc, and Thomas, Muriel

Published
2021
Full Text
View/download PDF

36. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

Author

Maes, Tamara, primary, Mascaró, Cristina, additional, Tirapu, Iñigo, additional, Estiarte, Angels, additional, Ciceri, Filippo, additional, Lunardi, Serena, additional, Guibourt, Nathalie, additional, Perdones, Alvaro, additional, Lufino, Michele M.P., additional, Somervaille, Tim C.P., additional, Wiseman, Dan H., additional, Duy, Cihangir, additional, Melnick, Ari, additional, Willekens, Christophe, additional, Ortega, Alberto, additional, Martinell, Marc, additional, Valls, Nuria, additional, Kurz, Guido, additional, Fyfe, Matthew, additional, Castro-Palomino, Julio Cesar, additional, and Buesa, Carlos, additional

Published
2018
Full Text
View/download PDF

37. Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Author

Quek, Lynn, primary, David, Muriel, additional, Kennedy, Alison, additional, Metzner, Marlen, additional, Amatangelo, Michael, additional, Shih, Alan H., additional, Stoilova, Bilyana, additional, Karamitros, Dimitris, additional, Quivoron, Cyril, additional, Heiblig, Mael, additional, Willekens, Christophe, additional, Saada, Veronique, additional, Peniket, Andrew, additional, Bernard, Olivier, additional, Agresta, Sam, additional, Yen, Katharine, additional, Stein, Eytan M., additional, De Botton, Stephane, additional, Thakurta, Anjan, additional, Levine, Ross L., additional, Penard-Lacronique, Virginie, additional, and Vyas, Paresh, additional

Published
2017
Full Text
View/download PDF

38. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Author

de Botton, Stephane, Mondesir,Johanna, Willekens,Christophe, and Touat,Mehdi

Subjects
Journal of Blood Medicine
Abstract

Johanna Mondesir1,2 Christophe Willekens3–5 Mehdi Touat6,7 Stéphane de Botton3–5 1Service d’Immunopathologie Clinique, Hôpital Saint Louis, 2CNRS UMR8104, INSERM U1016, Institut Cochin, Université Paris Descartes, Paris, 3Gustave Roussy, Université Paris-Saclay, Service d’Hématologie Clinique, 4INSERM U1170, Gustave Roussy, Université Paris-Saclay, Villejuif, 5Faculté de médecine Paris-Sud, Kremlin-Bicêtre, 6AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière – Charles Foix, Service de Neurologie 2-Mazarin, Paris, 7Gustave Roussy, Université Paris‑Saclay, Département d’Innovation Thérapeutique et d’Essais Précoces, Villejuif, France Abstract: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations inIDH1/2confer a gain-of-function in cancer cells, resulting in the accumulation and secretion in vast excess of an oncometabolite, the D-2-hydroxyglutarate (D-2HG). Overproduction of D-2HG interferes with cellular metabolism and epigenetic regulation, contributing to oncogenesis. Indeed, high levels of D-2HG inhibit α-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases, leading to histone and DNA hypermethylation and finally a block in cell differentiation. Furthermore, D-2HG is a biomarker suitable for the detection ofIDH1/2mutations at diagnosis and predictive of the clinical response. Finally, mutant-IDH1/2 enzymes inhibitors have entered clinical trials for patients withIDH1/2mutations and represent a novel drug class for targeted therapy. Keywords: tumor metabolism, epigenetic, oncogene, IDH1, IDH2, glioma, acute myeloid leukemia, 2-HG, targeted therapies

Published
2016

39. Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines

Author

Zhang, Yanyan, primary, He, Liang, additional, Selimoglu-Buet, Dorothée, additional, Jego, Chloe, additional, Morabito, Margot, additional, Willekens, Christophe, additional, Diop, M'boyba Khadija, additional, Gonin, Patrick, additional, Lapierre, Valérie, additional, Droin, Nathalie, additional, Solary, Eric, additional, and Louache, Fawzia, additional

Published
2017
Full Text
View/download PDF

40. Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

Author

Saleh, Khalil, primary, Michot, Jean-Marie, additional, Danu, Alina, additional, Lazarovici, Julien, additional, Khalifé-Saleh, Nadine, additional, Ghez, David, additional, Chahine, Claude, additional, Dakdouki, Yolla, additional, Fahri, Jonathan, additional, Willekens, Christophe, additional, Boros, Angela, additional, Arfi-Rouche, Julia, additional, Maroun, Pierre, additional, Deutsch, Eric, additional, Ribrag, Vincent, additional, and Mazeron, Renaud, additional

Published
2016
Full Text
View/download PDF

41. Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

Author

Lee, Stanley Chun-Wei, primary, Dilai, Khrystyna, additional, Obeng, Esther A., additional, Kim, Eunhee, additional, Micol, Jean-Baptiste, additional, Yoshimi, Akihide, additional, Willekens, Christophe, additional, Inoue, Daichi, additional, Saada, Véronique, additional, Cho, Hana, additional, Chung, Young Rock, additional, Palacino, James, additional, Seiler, Michael, additional, Buonamici, Silvia, additional, Smith, Peter, additional, Ebert, Benjamin L., additional, Bradley, Robert, additional, and Abdel-Wahab, Omar, additional

Published
2016
Full Text
View/download PDF

42. Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Author

Somervaille, Tim, primary, Salamero, Olga, additional, Montesinos, Pau, additional, Willekens, Christophe, additional, Perez Simon, Jose Antonio, additional, Pigneux, Arnaud, additional, Recher, Christian, additional, Popat, Rakesh, additional, Molinero, Cesar, additional, Mascaro, Christina, additional, Maes, Tamara, additional, and Bosch, Francesc, additional

Published
2016
Full Text
View/download PDF

43. Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Author

Saleh, Khalil, primary, Willekens, Christophe, additional, Martin, Jean Edouard, additional, Kossai, Myriam, additional, Khalifé-Saleh, Nadine, additional, Saada, Véronique, additional, Auger, Nathalie, additional, Danu, Alina, additional, Lazarovici, Julien, additional, Leary, Alexandra, additional, Delaloge, Suzette, additional, Bourhis, Jean Henri, additional, Solary, Éric, additional, Koscielny, Serge, additional, de Botton, Stephane, additional, and Micol, Jean-Baptiste, additional

Published
2016
Full Text
View/download PDF

44. Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Author

Da Rocha, Audrey, Cassinat, Bruno, Heiblig, Mael, Recher, Christian, Bertoli, Sarah, Bonmati, Caroline, Roth-Guepin, Gabrielle, Zilliox, Anne, Laloi, Marie, Hunault, Mathilde, Berthon, Céline, Duployez, Nicolas, Willekens, Christophe, Gallego Hernanz, Maria Pilar, Ochmann, Marlene, Cluzeau, Thomas, Chermat, Fatiha, Caulier, Alexis, Raffoux, Emmanuel, Fenaux, Pierre, Marolleau, Jean Pierre, Ades, Lionel, and Lebon, Delphine

Abstract

INTRODUCTION:

Published
2023
Full Text
View/download PDF

45. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Author

Mondesir,Johanna, Willekens,Christophe, Touat,Mehdi, de Botton,Stephane, Mondesir,Johanna, Willekens,Christophe, Touat,Mehdi, and de Botton,Stephane

Abstract

Johanna Mondesir1,2 Christophe Willekens3–5 Mehdi Touat6,7 Stéphane de Botton3–5 1Service d’Immunopathologie Clinique, Hôpital Saint Louis, 2CNRS UMR8104, INSERM U1016, Institut Cochin, Université Paris Descartes, Paris, 3Gustave Roussy, Université Paris-Saclay, Service d’Hématologie Clinique, 4INSERM U1170, Gustave Roussy, Université Paris-Saclay, Villejuif, 5Faculté de médecine Paris-Sud, Kremlin-Bicêtre, 6AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière – Charles Foix, Service de Neurologie 2-Mazarin, Paris, 7Gustave Roussy, Université Paris‑Saclay, Département d’Innovation Thérapeutique et d’Essais Précoces, Villejuif, France Abstract: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations in IDH1/2 confer a gain-of-function in cancer cells, resulting in the accumulation and secretion in vast excess of an oncometabolite, the D-2-hydroxyglutarate (D-2HG). Overproduction of D-2HG interferes with cellular metabolism and epigenetic regulation, contributing to oncogenesis. Indeed, high levels of D-2HG inhibit α-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases, leading to histone and DNA hypermethylation and finally a block in cell differentiation. Furthermore, D-2HG is a biomarker suitable for the detection of IDH1/2 mutations at diagnosis and predictive of the clinical response. Finally, mutant-IDH1/2 enzymes inhibitors have entered clinical trials for pati

Published
2016

46. Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Author

Willekens, Christophe, primary, Micol, Jean-Baptiste, additional, Poinsignon, Vianney, additional, Quivoron, Cyril, additional, Saada, Véronique, additional, Broutin, Sophie, additional, Terroir-Cassou-Mounat, Marie, additional, Ghez, David, additional, Bourhis, Jean-Henri, additional, Bosq, Jacques, additional, Ribrag, Vincent, additional, Paci, Angelo, additional, Lacronique-Penard, Virginie, additional, and De Botton, Stéphane, additional

Published
2015
Full Text
View/download PDF

47. Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Author

Willekens, Christophe, primary, Paci, Angelo, additional, Koscielny, Serge, additional, Marceau, Alice, additional, Micol, Jean-Baptiste, additional, Broutin, Sophie, additional, Quivoron, Cyril, additional, Saada, Véronique, additional, Poinsignon, Vianney, additional, Griscelli, Franck, additional, Ribrag, Vincent, additional, Castilla-Llorente, Cristina, additional, Preudhomme, Claude, additional, Lacronique-Penard, Virginie, additional, and De Botton, Stéphane, additional

Published
2015
Full Text
View/download PDF

49. The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Author

Sakr, Riwa, Pilorge, Sylvain, De Botton, Stephane, Chahine, Claude, Coman, Tereza, Adler, Marcel, Micol, Jean-Baptiste, Pasquier, Florence, Willekens, Christophe, Danu, Alina, Lazarovici, Julien, Ghez, David, Solary, Eric, Ribbag, Vincent, Bourhis, Jean-Henri, and Castilla-LLorente, Cristina

Published
2017
Full Text
View/download PDF

50. Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Author

Willekens, Christophe, Saada, Veronique, Broutin, Sophie, Delahousse, Julia, Renneville, Aline, Petrovanu, Cynthia, Marzac, Christophe, Micol, Jean-Baptiste, Solary, Éric, Pasquier, Florence, Lazarovici, Julien, Ribrag, Vincent, Preudhomme, Claude, Quivoron, Cyril, Penard-Lacronique, Virginie, Paci, Angelo, and de Botton, Stephane

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results